NCT03498521 2025-11-19
CUPISCO
Hoffmann-La Roche
Phase 2 Completed
Clinical Trials
9 trialsNCT02304809 2025-08-01
AcSé
UNICANCER
Phase 2 Active not recruiting
NCT04341181 2025-07-25
ProTarget
Rigshospitalet, Denmark
Phase 2 Recruiting
NCT04551521 2025-01-08
CRAFT: The NCT-PMO-1602 Phase II Trial
German Cancer Research Center
Phase 2 Completed
NCT04817956 2024-02-29
IMPRESS-N
Oslo University Hospital
Phase 2 Recruiting
NCT02925234 2024-01-24
DRUP
The Netherlands Cancer Institute
Phase 2 Recruiting
NCT03239015 2022-03-04
Efficacy and Safety of Precision Therapy in Refractory Tumor
Shanghai Changzheng Hospital
Phase 2 Unknown
NCT02142036 2019-03-13
MetAction
Oslo University Hospital
Phase 2 Completed
NCT01286753 2016-09-07
A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation
Hoffmann-La Roche
Phase 2 Completed